Aspirin related platelet reactivity as a determinant of ten year survival in high risk non-ST segment elevation myocardial infarction (NSTEMI) patients

Khan, Nazish, Mamas, Mamas A., Moss, Alexandra, Gorog, Diana A., Nightingale, Peter, Armesilla, Angel, Smallwood, Andrew, Munir, Shahzad, Khogali, Saib, Wrigley, Ben and Cotton, James M. (2020) Aspirin related platelet reactivity as a determinant of ten year survival in high risk non-ST segment elevation myocardial infarction (NSTEMI) patients. Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis, 196. pp. 523-525. ISSN 0049-3848
Copy

Aspirin, the most commonly prescribed antiplatelet agent in clinical practice, forms a cornerstone of management in patients with established cardiovascular disease (CVD). The clinical efficacy and safety of aspirin when prescribed for secondary prevention is supported by a robust evidence base demonstrating a 24% reduction in mortality and a 25% reduction in serious adverse events without any increase in bleeding complications in the context of an acute myocardial infarction [ 1 ]. Nevertheless, numerous studies have shown that the antiplatelet effect of aspirin is not uniform and is often sub-optimal in a sizable proportion of patients [ 2 , 3 ]. Inadequate platelet inhibition following the administration of aspirin is associated with recurrent cardiovascular events and adverse outcomes in patients with coronary artery disease [ 2 ].


picture_as_pdf
EHJ_Selatogrel_stable_CAD_phase_2_study_Final_accepted_version.pdf
subject
Submitted Version
Available under Creative Commons: BY-NC-ND 4.0

View Download

Atom BibTeX OpenURL ContextObject in Span OpenURL ContextObject Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation METS MODS RIOXX2 XML Reference Manager Refer ASCII Citation
Export

Downloads